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Objective: Uncertainty surrounds the risks of lithium use
during pregnancy in women with bipolar disorder. The au-
thors sought to provide a critical appraisal of the evidence
related to the efficacy and safety of lithium treatment during
the peripartum period, focusing on women with bipolar dis-
order and their offspring.
Methods: The authors conducted a systematic review and
random-effects meta-analysis assessing case-control, co-
hort, and interventional studies reporting on the safety (pri-
mary outcome, any congenital anomaly) or efficacy (primary
outcome, mood relapse prevention) of lithium treatment
during pregnancy and the postpartum period. The Newcastle-
Ottawa Scale and the Cochrane risk of bias tools were used to
assess the quality of available PubMed and Scopus records
through October 2018.
Results: Twenty-nine studies were included in the analyses
(20 studies were of good quality, and sixwere of poor quality;
one study had an unclear risk of bias, and two had a high risk
of bias). Thirteen of the 29 studies could be included in the
quantitative analysis. Lithium prescribed during pregnancy
was associated with higher odds of any congenital anomaly
(N=23,300, k=11; prevalence=4.1%, k=11; odds ratio=1.81,
95% CI=1.35–2.41; number needed to harm (NNH)=33, 95%
CI=22–77) and of cardiac anomalies (N=1,348,475, k=12;
prevalence=1.2%, k=9; odds ratio=1.86, 95% CI=1.16–2.96;
NNH=71, 95% CI=48–167). Lithium exposure during the first
trimester was associated with higher odds of spontaneous
abortion (N=1,289, k=3, prevalence=8.1%; odds ratio=3.77,
95% CI=1.15–12.39; NNH=15, 95% CI=8–111). Comparing
lithium-exposed with unexposed pregnancies, significance
remained for any malformation (exposure during any preg-
nancyperiodor thefirst trimester) andcardiacmalformations
(exposure during the first trimester), but not for spontaneous
abortion (exposure during the first trimester) and cardiac mal-
formations (exposure during any pregnancy period). Lithium
was more effective than no lithium in preventing postpartum
relapse (N=48, k=2; odds ratio=0.16, 95% CI=0.03–0.89; num-
ber needed to treat=3, 95% CI=1–12). The qualitative synthesis
showed that mothers with serum lithium levels ,0.64 mEq/L
and dosages,600 mg/day had more reactive newborns with-
out an increased risk of cardiac malformations.
Conclusions: The risk associated with lithium exposure at
any time during pregnancy is low, and the risk is higher for
first-trimesterorhigher-dosageexposure. Ideally, pregnancy
should be planned during remission from bipolar disorder
and lithium prescribed within the lowest therapeutic range
throughout pregnancy, particularly during the first trimester
and the days immediately preceding delivery, balancing the
safety and efficacy profile for the individual patient.
AJP in Advance (doi: 10.1176/appi.ajp.2019.19030228)
The management of women with bipolar disorder during
both the antenatal and postnatal periods is associated with
major obstetric and mental health concerns because of the
inherent risks related to bipolar disorder itself as well as its
treatment (1). Balancing the benefits and risks of intervention
for bipolar disorder is therefore crucial. This is particularly so
because women with bipolar disorder are typically young at
illness onset, placing them at risk for episodes throughout
their reproductive years (2), although fertility rates among
womenwith bipolar disorder are lower than those among the
general population (3).
Womenwithbipolardisorderoftenexhibit a rapid-cycling
course,which is also associatedwith a lifetimepredominance
of depression with mixed features, as well as long latency
between treatment initiation and the onset of therapeutic
effects for a wide range of mood-stabilizing medications,
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including lithium (4). Both bipolar disorder itself and the
abrupt discontinuation of lithium at any time before concep-
tion, during pregnancy, or during the breastfeeding period
carry a significant risk for relapse and recurrence (5),
potentially increasing the risk for suicide as well as of psy-
chosocial and general medical deterioration (6, 7). Medico-
legal issues, as well as concerns about potential detrimental
effects on fetal development associated with lithium expo-
sure during pregnancy and the lack of a consistent position
across most guidelines, may lead to the premature and often
abrupt interruption of lithium treatment. In fact, the pre-
scribing clinician or the insufficiently informed patient may
discontinue lithium without carefully weighing the risk-
benefit profile for the mother and the offspring.
According to a recent meta-analysis assessing maternal
and infant outcomes associated with lithium use during
pregnancy from six international cohorts (8), lithium expo-
sure during the first trimester was associated with a relative
171% increase in the odds of a major malformation (an ab-
solute risk of 7.4% with lithium, compared with 4.3% in
offspring not exposed to lithium), and a 162% increase in the
odds of neonatal readmission rates within 4 weeks of birth
comparedwith anunexposedmooddisorder reference group
(an absolute risk of 27.5% in offspring exposed to lithium,
compared with 14.3% in offspring not exposed). In contrast,
the odds for major malformations in exposed offspring, es-
pecially neural tube defects and Ebstein’s anomaly (down-
ward displacement of the tricuspid valve into the right
ventricle and variable levels of right ventricle hypoplasia) did
not significantly differ from those in unexposed offspring (8).
Aside from lithium teratogenicity, neonatal toxicity events
may occur in offspring exposed to lithium during labor, in-
cluding the so-called floppy baby syndrome (characterized
by cyanosis and hypotonicity), neonatal hypothyroidism,
and nephrogenic diabetes insipidus (9). Nonetheless, the ap-
praisal of the risk for long-term adverse neurodevelopmental
consequences of intrauterine exposure to lithium is ham-
pered by the fact that most studies have compared exposed
children with children from unaffected populations, which
did not allow for correction of the potential influence of
genetic predisposition or parental psychiatric illness (10).
It has been shown that lithium is the most effective
prophylactic treatment option for bipolar disorder (as well
as other psychiatric disorders, including recurrent major
depression and schizoaffective disorder), even during the
perinatal period if properly used, and that its side effect
profile is more favorable than generally assumed (11).
Moreover, the U.S. Food and Drug Administration (FDA)
issued a warning about the use of antipsychotics during
the peripartum period (12), and the risk of fetal valproate
and carbamazepine syndrome (and the confirmed neuro-
developmental teratogenicity of valproate) contraindicates
the use of such medications during this phase of the female
reproductive cycle (13). Further complicating the clini-
cal decision is the fact that most evidence on medications
other than lithium is anecdotal or outdated. While specific
guidelines, such as the National Institute for Health and
Care Excellence guidelines (14), state that the use of lithium
is contraindicated, especially during the first trimester of
pregnancy, “evidence-based” guidelines are not necessarily
concordant with “consensus-based” guidelines, which need
to weight and integrate evidence for efficacy and safety (1).
Such a difference is particularly true for suggested algo-
rithms,which can change dramatically depending onwhether
safety or efficacy is prioritized, shifting the ultimate question
for the clinician from whether or not to use lithium during
the peripartum period in women with bipolar disorder to how
to use lithium optimally in this population (15).
Our aim in this systematic reviewandmeta-analysiswas to
provide a critical appraisal of the evidenceof both the efficacy
and the safety of lithium during the peripartum period, fo-
cusing on women with bipolar disorder and their offspring,
in order to inform prescribing clinicians.
METHODS
We followed the procedures outlined in the 2015 update of
the Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) (http://www.prisma-
statement.org/) (16) and the Meta-Analysis of Observational
Studies in Epidemiology (MOOSE) guidelines (17), following
an a priori (but unpublished) protocol.
Search Strategy
Four authors divided into two teams (E.M., E.S., M.F., A.A.)
independently searched the PubMed and Scopus databases
for records since database inception through October 18,
2018. The following search strings were used in PubMed and
then adapted for Scopus: search 1: “(pregnancy OR pregnant
OR pre-natal OR prenatal OR peri-natal OR perinatal OR
post-natal OR postnatal OR delivery OR pre-partum OR
prepartum OR peri-partum OR peripartum OR post-partum
ORpostpartum)”; search 2: lithium; search 3: searches 1 AND
2 with the filter “humans.” Finally, the results of the elec-
tronic searches were augmented by a manual search and
cross-referencing of the reference lists of relevant studies.
Eligibility Criteria
We limited our search to original studies (of any design)
reporting quantitative data on the efficacy and safety out-
comes of women treated with lithium during pregnancy and
the postpartum period, and/or lithium exposure to the fetus
and/or the newborn. However, we did not focus on risks for
the newborn related to lithium treatment during breast-
feeding (see reference 18 for a review).
We excluded review articles, case reports or series (i.e.,
N,10 subjects), expert opinion, animal studies, and studies
without quantitative data. In the case of multidiagnostic
samples, we excluded studies that did not provide data
separately for women with bipolar disorder. We included
studies without a control group for the qualitative synthesis
of the evidence, whereas the quantitative extraction was
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performed only on those studies that used a control group,
allowing an effect size computation.
Meta-Analysis Primary and Secondary Outcomes, and
Qualitative Synthesis
In themeta-analysis, the primary safety outcomewas the risk
of any malformation; the primary efficacy outcome was
“relapse prevention” (whether during pregnancy or in the
postpartum period). Except for lactation-related outcomes,
we included any other safety and primary outcomes during
pregnancy and the postpartum period that were reported in
eligible studies (secondary outcomes). In the qualitative
synthesis, we also extracted the main safety and efficacy
outcomes during pregnancy and the postpartum period from
studies without a control group, and we provided a narrative
synthesis of eligible studies’ findings grouped by study safety
and efficacy and study design.
Data Extraction
The retrieved records were independently assessed by two
authors (M.S., M.F.) at the title and abstract level, followed
by a detailed evaluation of the full text. Any inconsistencies
were resolved by consensus or inclusion of a third reviewer
blind to the other reviewers’ decisions (A.A.).
The following information was extracted independently
by twoauthors (E.S., E.M.) for the lithiumandcontrol groups:
author, publication year, study design, study aim (efficacy,
safety), pregnancy (including gestational week) or post-
partum period, and sample size. We extracted quantitative
outcomemeasures related to efficacy and safety, aswell as the
description of the main findings.
We also extracted the information needed to assess the
quality of the included studies with the Newcastle-Ottawa
Scale (19) for observational studies and the Cochrane risk
of bias tool for randomized studies (20). We adopted the
thresholds for converting Newcastle-Ottawa Scale scores
into “good,” “fair,” and “poor” quality criteria, previously
described by systematic reviews (21).
Evidence Synthesis
We conducted a narrative synthesis of the results of the
studies that fulfilled thepredeterminedeligibility criteria.We
performed a random-effects meta-analysis (22) of outcomes
reported in at least two studies, given the population het-
erogeneity, using theComprehensiveMeta-Analysispackage,
version 2 (23). Effect sizes and their 95% confidence intervals
were computed on the basis of the type of results reported in
each study; adjusted effect sizes were prioritized whenever
both adjusted and unadjusted estimates were available.
Publication bias was assessed when at least three studies
provided results for a given outcome, using visual inspection
of funnel plots and Egger’s test (whereby p,0.05 indicates
significant publication bias) (24). We calculated the number
needed to harm (NNH) or the number needed to treat (NNT)
for harm or benefit, respectively, by dividing 1 by the risk
difference of event rates in each group. Finally, we calculated
the prevalence of adverse health outcomes from cohort
studies to put association metrics into an epidemiologic
context.
RESULTS
Synthesis of the SearchResults andMainCharacteristics
of the Included Studies
The searchflowand themain results are reported in Figure 1.
Of 3,067 unduplicated records, 57 full-text articles were
retrieved and assessed for eligibility. (The list of studies
excluded after full-text assessment, with the reasons, is
available from the authors on request.) Of these, 33 articles
were excluded because they did not report data on the safety
or efficacy of lithium (14 articles), were reviews (14 articles),
were not published in English (three articles), or were case
reports (two articles) (see Table S1 and references in the
online supplement). The remaining 24 articles covered
29 studies that reported qualitative information on either the
safety or the efficacy of lithium during pregnancy or the
postpartum period for the exposed women and/or on safety
for the fetus or newborn, suitable for the narrative synthesis,
and 13 studies (covered by eight articles) were suitable for
the meta-analysis.
The characteristics of the included studies, together with
a narrative synthesis of the study results, are reported in
Table 1, and the quality of the appraised evidence is outlined
in Table S2 in the online supplement. Briefly, besides pre-
vious studies that represent the first attempts to quantify the
effects of lithium in pregnancy and were of poor quality,
relevant information on lithium dosage and related safety
are presented in Table S2 from more recent studies.
Quality of the Included Studies
Overall, among case-control studies and cohort studies,
20 had “good” quality and six were of “poor” quality overall,
based on the Newcastle-Ottawa Scale (see Table S2 in the
online supplement), according to systematic reviews (21).
The Cochrane risk of bias tool indicated an unclear risk for
bias for one interventional study, and two had a high risk of
bias (two randomized controlled trials, one trial without a
control group). All studies included in the meta-analysis on
safety outcomes had good quality on the Newcastle-Ottawa
Scale, and studies included in the efficacy outcomes meta-
analysis had a high risk of bias.
Meta-Analysis
The available information from eight studies reporting on
13 comparisons (k) between lithium-exposed and unexposed
control subjects (both in the general population and patients
with affective disorders not exposed to lithium) (2, 8, 11,
25–29) (N=1,349,563 pregnancies) allowed pooling of data on
the effects of antenatal exposure to lithium regarding risk of
spontaneous abortion (two studies, N=1,289), preterm birth
(usually definedas a gestationperiod,37weeks) (six studies,
N=23,695), low birth weight (three studies, N=23,238), any
ajp in Advance ajp.psychiatryonline.org 3
FORNARO ET AL.
congenital anomaly (four studies, N=23,046), and cardiac
congenital anomalies (four studies, N=1,348,475).
Available data allowed additional analyses compar-
ing lithium-exposed pregnancies with unexposed general-
population pregnancies regarding preterm birth (two studies,
N=845) and any congenital anomaly (two studies, N=1,003).
The data also allowed comparisons between lithium-exposed
and unexposed pregnancies in women with affective disor-
ders regarding spontaneous abortion (two studies, N=441),
preterm birth (six studies, N=23,001), low birth weight (three
studies, N=22,527), any congenital anomaly (four studies,
N=22,225), and cardiac anomalies (four studies, N=24,699)
(Table 2).
Spontaneous abortion. Lithium exposure during the first
trimester of pregnancy was associated with a significantly
increased risk of spontaneous abortion (2, 26) (two studies,
k=3, N=1,289; odds ratio=3.77, 95% CI=1.15–12.39; I2=
86.56%; NNH=15, 95% CI=8–111, p=0.03; I2=56.17%) when
comparedwith any unexposed group.When comparedwith
unexposed patients with affective disorders, the difference
was not significant (two studies, k=2, N=541; odds ra-
tio=2.46, 95% CI=0.56–10.77; I2=82.1%) (Tables 2 and 3 and
Figure 2).
Preterm birth and low birth weight. Lithium exposure during
pregnancy was not associated with a significantly increased
risk of preterm birth (2, 8, 26–29) when compared with any
unexposed group (six studies, k=13, N=23,695; odds ra-
tio=1.42, 95% CI=0.98–2.06; I2=60.6%), with unexposed
patients with affective disorders (six studies, k=11, N=23,001;
odds ratio=1.34, 95% CI=0.89–2.01; I2=62.8%), or with the
unexposed general population (two studies, k=2,N=845; odds
ratio=2.22, 95% CI=0.99–4.97; I2=6.68%) (Table 2). Lithium
exposure during pregnancy was not significantly associated
with low birth weight (2, 8, 26) when compared with any
unexposed group (three studies, k=9, N=23,238; odds ra-
tio=0.99, 95% CI=0.84–1.19; I2=0%) or with unexposed pa-
tients with affective disorders (three studies, k=8, N=22,527;
odds ratio=1.07, 95% CI=0.85–1.34; I2=0%) (Table 2 and
Figure 2). Results were similar when exposure occurred
specifically during the first trimester (Table 3).
FIGURE 1. Flow diagram of study selection for qualitative synthesis and a meta-analysis
Excluded (N=33)
• Reviews (N=14)
•  No effi  cacy or safety data 
on lithium (N=14)
• Not in English (N=3)
• Case reports (N=2)




Full-text articles assessed for eligibility 
(N=57)
Studies included in qualitative synthesis 
(N=24 publications, covering 29 studies)a
Studies included in quantitative synthesis 
(meta-analysis)
(N=8 publications, covering 13 studies)a
Records identifi ed through PubMed and 
Scopus searches
(N=4,222)



































aOne publication covered six original cohort studies.
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Main Safety or Tolerability Results
(Systematic Qualitative Review)
Safety: case-control studies
Edmonds 1990 (38) 68 Birth Defects Monitoring
Program (USA)
Pregnancy Lithium exposure in births
with versus without
Ebstein’s anomaly
Among the 34 infants with confirmed
Ebstein’s anomaly and the infants in the
control group, we found none whose
mother had a history of manic-
depressive illnessesor lithiumuseduring
pregnancy.











Onecaseof inutero lithiumexposure in the
168 mother-child-pair control group
with neuroblastoma, but no cases in
mothers of 59 children with Ebstein’s
anomaly. The results can rule out (with
80% power and an alpha of 0.05)
increased risk ofmore than 28-fold. This
potential risk is much lower than the
historically claimed 500-fold computed
from the uncontrolled Danish registry
(40).
Czeizel 1990 (41) 32,224 Hungarian Case-Control
Surveillance of
Congenital Anomalies
Pregnancy Lithium exposure in births
with versus without
cardiac anomaly
No statistically significant association was
found between the use of lithium and
the appearance of any congenital
anomaly.







Lithium exposure in births
with Ebstein’s anomaly
versus lithiumexposure
in births with another
cardiac anomaly
Ebstein’s anomaly was associated with
maternal mental health problems
generally rather than lithium or
benzodiazepines specifically; therefore,
changing or stopping medications may
not be preventive.









No statistically significant association was
found between malformations and the
use of lithium.
Safety: prospective cohort studies










This was is a questionnaire follow-up of
the physical and mental development
of lithium children who were not
malformed at birth. Sixty lithium-
exposed children were examined, and
their unexposed siblings served as a
control group. The data do not reveal
any increased frequency of physical or
















No statistically significant difference was
found between groups in total
malformation rate (2.8% lithium group,
2.4% control group), and no
difference was found in risk ratio for
congenital malformation, cardiac
malformation, or Ebstein’s anomaly.
Similar rates of spontaneous
abortion were seen in the lithium and
nonlithium groups (9% and 8%), as well
as similar rates of premature delivery
(4% and 5%).
continued

























There were significantly more miscarriages
and elective terminations in pregnancies
exposed to lithium (16.4% and 9.3%) and
among mothers with bipolar disorder
(8.3% and 8.3%) than in an unexposed
group (5.7% and2%). The rateof preterm
deliveries was significantly higher in the
lithium group (13.7%) and the bipolar
disorder group unexposed to lithium
(10.2%) compared with unexposed
pregnancies (6.0%). The rate of major
congenital anomalies after exclusion of
genetic or cytogenetic anomalies was
not significantly different among the
three groups from the Israeli register.
However, when data from Australia and
Canada were also considered, babies
exposed to lithium had significantly
higher rates of major anomalies without
chromosomal or genetic conditions
(8.6% and 2.5%), cardiovascular
anomalies (3.9% and 0.5%),
cardiovascular anomalies excluding
resolved cases (2.6% and 0.2%), and
non-cardiovascular anomalies (5.9%
and 2%).









The rate of all complications except
gestational diabetes was consistently
higher in the high lithium exposure
group. In particular, the rates ofCNS and
neuromuscular complications were
significantly higher, the duration of
infant hospital stays was significantly
longer, and 1-minute Apgar scoreswere
significantly lower in the high lithium
exposure group. The rates of preterm
delivery, low birth weight, and infant
respiratorycomplicationswerehigher in
the high lithium exposure group than in
the low lithium exposure group, but the
differences only approached
significance.
Safety: retrospective cohort studies






Of the 118 children exposed to lithium, five
were stillborn and seven died within the
first week of life; six of these twelve
children had malformations. The total
number of children with malformations
was nine, of which two had Down’s
syndrome.
Weinstein 1975 (46) 143 Register of Lithium Babies
(USA)
Pregnancy Malformations in babies
exposed to lithium
The 143 cases of lithium use during
pregnancy recorded by the register
showed that infants exposed to lithium
appeared tohaveahigher thanexpected
ratio of cardiovascular anomalies (7.7%)
to all anomalies (9.1%) and may have an
increased risk of congenital heart
disease. The author believes that these
findings justify a conservative policy on
the use of lithium with fertile and
pregnant women.
continued
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Main Safety or Tolerability Results
(Systematic Qualitative Review)
Weinstein 1976 (47) 166 Register of Lithium Babies
(USA)
Pregnancy Malformations in babies
exposed to lithium
The ratio of Ebstein’s anomaly to all
reported nontrivial anomalies was 1:4.5;
the ratioofEbstein’sanomaly toall forms
of congenital heart disease to all
nontrivial malformations is 1:1.5. In the
register, the ratio of malformations of
the tricuspid valve and tricuspid atresia
to all cardiac anomalies was about 1:2.4,
and the ratio of tricuspid atresia to all
congenital heart defects in the baseline
studies was about 1:44. The maximum
frequencies of congenital
malformations reported to the register
(10.8%) did not substantially exceed the
expected incidence of such

















There was no statistically significant
differencebetweendeliveryoutcomeor
malformations inwomen on lithium and
women on other psychotropic drugs.
None of the infants with heart disease
had Ebstein’s anomaly.
Van der Lugt 2012 (48) 30 Perinatal Center, Leiden
University Medical
Center (Netherlands)
Pregnancy Cognition at follow-up
(3–15 years) in babies
exposed to lithium
This study reports the long-term outcome
of 30 children who were exposed to
lithium inutero andwere breastfed.One
child had signs of a minor neurological
dysfunction but without further clinical
implications. The results of the cognitive
tests were within normal limits. Growth,
behavior, and general development
were within the normal range.
Neurological screening and growth
measurements did not show any
significant abnormalities in the children;










no exposure, and in
mood disorder versus
controls
The children’s full-scale IQ, performance
IQ, and verbal IQ results did not differ
significantly between lithium-exposed
and unexposed groups. The processing
speedquotientwas significantly lower in
children exposed to mood disorders
than control subjects. Similar rates of
premature delivery and neonatal care














Cardiac malformations were present in
16 of the 663 infants exposed to lithium
(2.41%), 15,251 of the 1,322,955
unexposed infants (1.15%), and 27 of the
1,945 infants exposed to lamotrigine
(1.39%). The adjusted risk ratio for cardiac
malformations among infants exposed to
lithiumcomparedwithunexposedinfants
was 1.65 (95% CI=1.02–2.68). The risk
ratio was 1.11 (95% CI=0.46–2.64) for a
dosage #600 mg/day, 1.60 (95%
CI=0.67–3.80) for 601–900 mg/day,
and 3.22 (95% CI=1.47–7.02) for
more .900 mg/day. The prevalence
of right ventricular outflow tract
obstruction defects was 0.60% among
lithium-exposed infants and 0.18%
among unexposed infants (adjusted
risk ratio=2.66; 95% CI=1.00–7.06).
Results were similar when lamotrigine-
exposed infants were used as the
reference group.
continued





















In the cohort ofwomen exposed to lithium
during the first trimester of pregnancy,
there were no recorded congenital
abnormalities Women with lithium
prescriptions, irrespective of whether
they continued or discontinued the
medication, represented a high-risk





350 International Register of
Lithium Babies
(Scandinavia)
Pregnancy Preterm birth in babies
exposed versus
unexposed to lithium
The lithium-exposed cohort had a 36%
prevalence of preterm delivery. In a
cohort of 350 women, significantly
more infants in the lithium-exposed
group were born at ,38 weeks of
gestation (33%), compared with infants
born to mothers with manic-depressive
illness who did not receive lithium (13%)
or with mothers without a bipolar
disorder diagnosis (12%). Thus, the
relative risk of premature delivery for
women taking lithium during pregnancy
is 2.54 times that for women with or
withoutmanic-depressive illnesswhoare























Primary data from pregnant women and
their children from six international
cohorts based in the community and
clinics. Lithium exposure was not
associated with any of the predefined
pregnancy complications or delivery
outcomes. An increased risk for
neonatal readmission within 28 days of
birth was seen in the lithium-exposed
group compared with the reference
group (pooled prevalence, 27.5% [95%
CI=15.8–39.1] compared with 14.3%
[95% CI=10.4–18.2]; pooled adjusted
odds ratio=1.62 [95% CI=1.12–2.33]).
Lithium exposure during the first
trimester was associated with an
increased risk of major malformations
(pooled prevalence, 7.4% [95% CI=
4.0–10.7] compared with 4.3% [95% CI=
3.7–4.8]; pooled adjusted odds ratio=1.71
[95% CI=1.07–2.72]), but for major
cardiac malformations the difference
was not significant (2.1% [95% CI=0.5–3.7]
compared with 1.6% [95% CI=1.0–2.1];
pooled adjusted odds ratio=1.54
[95% CI=0.64–3.70]).









women using or not
using lithium
Lower relapse rates for lithium-treated
compared with non-lithium-treated
women during postpartum (odds
ratio=0.14, 95% CI=0–6.5). All relapsing
women were admitted to hospital with
moderate to severe episodes of mania,
and all except two (in the untreated
group) relapsed within 3 weeks of
parturition. The average duration of
inpatient stay was 7 weeks (range,
5–12 weeks), and four of six relapsing
women from the untreated group were
subsequently started on lithium
prophylaxis.
continued
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Any congenital anomaly. Lithium exposure during pregnancy
was associated with a significantly increased risk of any
congenital anomaly (2, 8, 25, 26) when compared with any
unexposed group (four studies, k=11, N=23,300; odds ra-
tio=1.81, 95% CI=1.35–2.41; I2=0%; NNH=33, 95% CI=22–77,
p,0.001; I2=6.6%). The association was significant in anal-
yses restricted to patients with affective disorders (four
studies, k=9, N=22,297; odds ratio=1.75, 95% CI=1.21–2.52;
I2=15.4%; NNH=38, 95% CI=20–333, p=0.03; I2=29.3%) and
when the referent was the unexposed general population
(two studies, k=2, N=1,003; odds ratio=2.03, 95% CI=
1.03–3.99; I2=0%; NNH=22, 95% CI=12–200, p=0.03; I2=0%)
(Table 2 and Figure 3). Results were similar for first-trimester
exposure (Table 3 and Figure 3). Finally, the major malfor-
mations considered were those diagnosed by age 1 year,
including singular and combined structural defects, syn-
dromes, sequences (groups of related anomalies that gen-
erally stem from a single initial major anomaly that alters
the development of other surrounding or related tissues or
structures), and associations—such as cardiovascular de-
fects, neural tube defects, hypospadias, and epispadias.
Major cardiac malformations were defined as atrial and
atrioventricular septal defects and Ebstein’s anomaly, but
excluding atrial septal defect, and excluding patent ductus
arteriosus in infants born before 37 weeks of gestation,
according to the European Surveillance of Congenital
Anomalies guide (30).
Cardiac anomalies. Lithium exposure during pregnancy was
associated with a significantly increased risk of cardiac
malformations (2, 8, 11, 25) (four studies, k=12, N=1,348,475;
odds ratio=1.86, 95% CI=1.16–2.96; I2=40.16%; NNH=71, 95%
CI=48–167, p,0.001; I2=4.62%) when compared with any
unexposed group and with the general population (three
studies, k=3, N=1,324,591; odds ratio=4.00, 95% CI=1.19–13.4,
p=0.03; I2=63.2%; NNH=37, 95% CI=19–1000, p=0.04;
I2=46.4%). When compared with unexposed patients with























women using or not
using lithium
Of the women with bipolar disorder
(N=41), 24.4% relapsed during
pregnancy, despite prophylaxis use by
themajority throughout pregnancy. The
postpartum relapse rate was highest in
women with bipolar disorder who
experienced mood episodes during
pregnancy (60%). Patients with bipolar
disorder require continuous prophylaxis
throughout pregnancy and the
postpartum period to reduce
peripartum relapse risk.
Efficacy: lithium group only interventional study










Bipolar recurrences of any polarity during
pregnancy occurred in 11.1% of the
women. The results support the efficacy
of lithium prophylaxis throughout
pregnancy in lithium-responding
women with bipolar I disorder. No
serious side effects were noted for
mother or baby.
Efficacy: retrospective cohort studies






















Rates of recurrence during the first
40 weeks after lithium discontinuation
were similar for pregnant and
nonpregnant women but then sharply
increased postpartum. The risk
was much lower with gradual
discontinuation. Recurrence rates were
similar for bipolar I and II disorders but
were higher in patients with a history of
fourormorepriorepisodesof illness and
for those who underwent rapid
discontinuation of lithium.







No difference was observed between
lithium and lamotrigine in the
prevention of severe postpartum
episodes.
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studies, k=9, N=24,699; odds ratio=1.59, 95% CI=0.91–2.77;
I2=35.4%) (Table 2 and Figure 4).
In the analysis of exposure during the first trimester,
lithium was associated with an increased risk of cardiac
malformations compared with any unexposed group (four
studies, k=11, N=1,348,403; odds ratio=1.96, 95%CI=1.28–3.00;
I2=29.92%; NNH=71, 95% CI=48–143, p#0.001; I2=11.8%).
The risk was identical to that for exposure during any preg-
nancy period (as all studies investigated exposure during the
first trimester) comparedwith thegeneralpopulation, andwas
again significantly increased compared with unexposed pa-
tients with affective disorders (four studies, k=8, N=24,627;
TABLE 2. Random-effects meta-analysis of the safety and efficacy outcomes of lithium exposure during any time of pregnancy and
























Ratiob 95% CI I2 (%) p NNHc 95% CI I2 (%) p




2 3 43 321 6 968 3.77 1.15–12.39 86.55 0.03 15 8–111 56.17 0.03
Preterm birth
(2, 8, 26–29)




3 9 NA 980 NA 22,258 0.99 0.84–1.19 0 0.99 143d 38 –83 NAd 0.48
Any congenital
anomaly
(2, 8, 25, 26)
4 11 69 1,195 889 22,105 1.75 1.23–2.48 25.96 ,0.01 33 22–77 6.61 ,0.01
Cardiac
anomaly
(2, 8, 11, 25)
4 12 43 1,508 15,604 1,346,967 1.86 1.16–2.96 40.16 ,0.01 71 48–167 4.62 ,0.01
Exposure to lithium at any time during pregnancy compared with unexposed general population
Preterm birth
(2, 27)








3 2 26 815 15,256 1,323,776 3.99 1.19–13.43 63.17 0.03 37 19–1000 46.36 0.04




2 2 43 321 18 220 2.46 0.56–10.77 82.09 0.23 24 9–42 35.61 0.21
Preterm birth
(2, 8, 26–29)




3 8 NA 980 NA 21,547 1.07 0.85–1.34 0 0.56 143d 38–83 NAd 0.48
Any congenital
anomaly
(2, 8, 25, 26)
4 9 69 1,013 865 21,284 1.75 1.21–2.52 15.35 ,0.01 38 20–333 29.31 0.03
Cardiac
anomaly
(2, 8, 11, 25)
4 9 42 1,508 348 23,191 1.59 0.91–2.77 35.44 0.10 91 50–500 0 0.01






2 2 4 35 7 13 0.16 0.03–0.89 55.81 0.04 —f 1–12 52.76 0.12
a Egger’s test p values were all nonsignificant (.0.05). NA=not applicable; NNH=number needed to harm; k=number of comparisons.
b Odds ratio was computed on the basis of the adjusted odds ratios in individual studies, where available.
c NNHwas computedon thebasis of unadjustedevents frequencies in the twogroups (lithiumversus no lithium) andpooleddata (not from individual cohorts) from
Munk-Olsen et al. (8).
d NNH was computed from pooled data from Munk-Olsen et al. only (8).
e In one study (8), control subjects included patients with major depressive disorder in addition to those with bipolar disorder (exact figures undisclosed).
f The number needed to treat (NNT) is 3.
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odds ratio=1.75, 95% CI=1.08–2.84; I2=19.99%; NNH=83, 95%
CI=48–333, p=0.01; I2=0%) (Table 3 and Figure 4).
Relapse. Lithium was significantly more effective than no
prophylaxis in preventing postpartum mood episodes (any
polarity; follow-up range, 4 weeks to 2 years) in womenwith
mooddisorders (two studies, k=2,N=48; odds ratio=0.16, 95%
CI=0.03–0.89; I2=52.7%; NNT=3, 95% CI=1–12, p=0.12; I2=
52.7%). The risk of relapse during pregnancies with lithium
exposure could not be computed because of insufficient data.
DISCUSSION
Our aim in this systematic review was to summarize the
evidence on the safety and efficacy of lithium use during
pregnancy and the postpartum period. The quantitative
synthesis showed that lithium exposure at any time during
pregnancy was associated with a significantly increased risk
of spontaneous abortion, any congenital anomaly, and cardiac
anomalies, but it was not related to preterm delivery and low
birth weight when compared with women with bipolar
disorderunexposed to lithiumorwith thegeneralpopulation.
When the control group was matched for the presence of an
underlying mood disorder, lithium use during the first tri-
mester of pregnancy was not associated with an increased
risk for spontaneous abortion but was still associated with a
significantly increased risk for any congenital malformations
and cardiac malformations, yet with low absolute risk.
During the first trimester of pregnancy, the risk of any
congenital anomaly retained statistical significance on strati-
fication of any comparison groups (odds ratio=1.75; 95%
CI=1.23–2.48, p=0.002; and odds ratio=1.81; 95% CI=1.35–2.41,
p#0.001). However, such association, although clinically rel-
evant, shouldbebalancedagainstseveralunhealthybehavioral





















Ratiob 95% CI I2 (%) p NNHc 95% CI I2 (%) p




3 43 321 61 968 3.77 1.15–12.39 86.55 0.03 15 8–111 56.17 0.03
Preterm birth
(2, 26)
3 24 269 54 890 1.72 0.96–3.08 60.61 0.07 29 11–48 51.97 0.12
Low birth
weight (2, 26)
3 NA 269 NA 890 1.01 0.80–1.28 9.13 0.99 NA NA NA
Any congenital
anomaly
(2, 8, 25, 26)
10 65 1123 889 22,105 1.81 1.35–2.41 0 ,0.001 32 21–77 8.80 0.001
Cardiac
anomaly
(2, 8, 11, 25)
11 42 1,436 15,604 1,346,967 1.96 1.28–3.00 29.92 ,0.01 71 48–143 11.8 ,0.001








3 26 815 15,256 1,323,776 3.99 1.19–13.43 63.17 0.03 37 19–1000 46.36 0.04




2 43 321 18 220 2.46 0.56–10.77 82.09 0.23 24 9–42 35.61 0.21
Preterm birth
(2, 26)
2 24 269 13 207 1.17 0.56–2.44 0 0.68 25 23–31 0 0.86
Low birth
weight (2, 26)
2 NA 269 NA 207 1.17 0.85–1.61 0 0.34 NA NA NA
Any congenital
anomaly
(2, 8, 25, 26)
8 65 941 865 21,284 1.75 1.21–2.98 15.35 ,0.01 37 19–333 32.41 0.03
Cardiac
anomaly
(2, 8, 11, 25)
8 41 1,436 348 23,191 1.75 1.08–2.84 19.99 0.02 83 48–333 0 0.01
a Egger’s test p values were all nonsignificant (.0.05). NA=not applicable; NNH=number needed to harm; k=number of comparisons.
b Odds ratio was computed on the basis of the adjusted odds ratio in individual studies, where available.
c NNHwas computed on the basis of unadjusted event frequencies in the two groups (lithium comparedwith no lithium) and frompooled data (not from individual
cohorts) from Munk-Olsen et al. (8).
d In one study (8), control subjects included patients with major depressive disorder in addition to those with bipolar disorder (exact figures
undisclosed).
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factors, such as smoking and alcohol consumption among
others, that are known to be associated with mood disor-
ders and illness episodes (either depressive or manic) and
which could themselves have a detrimental effect on both the
mother and the fetus or newborn.
Consistent with the timing of organogenesis, the risk of
cardiac anomalies was significantly higher in children of
lithium-exposed than unexposed patients with bipolar dis-
order during the first trimester of pregnancy, but not in those
of mothers exposed at any time of pregnancy. In contrast, the
meta-analysis by Munk-Olsen et al. (8) documented a sta-
tistically significant increased risk for major malformations
during the first trimester of pregnancy, but not for major
cardiac malformations. This discrepancy could be due to the
inclusion of larger samples in our analysis, especially those
provided by Patorno et al. (11). In this sense, we acknowledge
that some outcomes pooled in the present analyses should
be considered preliminary, especially in the context of few
FIGURE 2. Risk of spontaneous abortion, preterm birth, and low birth weight associated with lithium exposure at any time during
pregnancy
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comparisons and high between- and within-study hetero-
geneity as well as our inability to systematically stratify for
study design.
It is worth noting, however, that while we were able to
expand thesample sizeandstrengthen thestatisticalpowerof
our analysis, the previous study byMunk-Olsen et al. (8) also
documented the rate of neonatal readmission within 28 days
of birth, which was seen to be increased in the lithium-
exposed group compared with the unexposed mood disor-
der group. On the other hand, ourmeta-analysis included the
outcome “spontaneous abortion” (which yielded a statisti-
cally significant increased risk among lithium-exposed
women with bipolar disorder during any time and the first
trimester of pregnancy when compared with overall control
subjects: odds ratio=3.77, 95% CI=1.48–12.39, p=0.03), also
allowing comparison with general-population controls be-
yond that of lithium-exposed women with bipolar disor-
der (8).
Besides the period of exposure, lithium dosage also seems
to play a role in determining health outcomes of the fetus
and newborn. As outlined by our qualitative synthesis here,
the risk of cardiac malformations seems to triple with
dosages.900mg/day comparedwith dosages#600mg/day
(11), and amedian lithium serum level.0.64mEq/L seems to
increase the risk of neonatal complications, such as CNS,
cardiac, thyroid, hepatic, neuromuscular, renal, and re-
spiratory complications. Lowering the lithium dosage during
thefirst trimester, yet keeping itwithin the therapeutic range,
could minimize both the risk of malformations (compared
with higher dosages) and the risk of relapse compared with
lithium withdrawal. However, beyond safety concerns, it is
important tonote that lowering the lithiumdosage toward the
lower end of the therapeutic range (usually defined as 0.6–1.2
mEq/L) may result in suboptimal dosages for patients who
respond to concentrations $0.8 mEq/L. This potential
complication is crucial especially for themost severe cases of
bipolar disorder (e.g., those with psychotic features and/or
high risk for suicidal behavior). Lowering lithium levels on
the days immediately before delivery (yet with prompt dos-
age resumption immediately after delivery) may minimize
FIGURE 3. Risk of any congenital anomaly associated with lithium exposure at any time during pregnancy and during the first trimester
compared with unexposed women (either bipolar disorder or general-population controls)
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neonatal complications,with thenewbornmore vital and less
sedated, with recommendations on this topic varying slightly
across the international guidelines that we reviewed (31).
However, currently, it is impossible to determine what the
potential harmfulness of lithium exposure to the newborn
during the delivery may be compared with exposure during
pregnancy. In other words, the recommendation to swiftly
resume the patient’s regular lithium dosage soon after de-
livery may need to be decided on a case-by-case basis, also
keeping in mind the slight increase of lithium serum levels in
the postpartum period compared with the last trimester of
pregnancy. Since different women benefit from different
lithiumdosages, lithiumdosing needs to be individualized on
the basis of prepregnancy relationships between lithium
dosage, serum level, efficacy, and tolerability, which must
be ascertained anamnestically and, ideally, via periodic sam-
pling of lithium serum levels during pregnancy (32).
Clinicians need to be aware of and consider that lithium
serum levels fluctuate during pregnancy. Specifically, an in-
creased glomerular filtration rate leads to a 24% mean re-
duction in lithium blood levels during the first trimester, 36%
during the second trimester, and21%during the last trimester
of pregnancy; in contrast, the serum levels of lithiummay rise
by 9% during the postpartum period, as detailed elsewhere
(32). Close monitoring of the pregnant woman’s serum
lithium levels is therefore crucial to informclinical choiceson
the basis of the physiological fluctuations occurring during
pregnancy to avoid suboptimal therapeutic dosing for the
pregnant woman, or potentially toxic doses thereafter, es-
pecially for the infant, in whom the adverse neonatal effects
of lithium, such as hypoglycemia, cardiac arrhythmia, thy-
roid dysfunction, and neonatal lithium toxicity, are dose
related (32).
However, considering the significant publication bias on
the matter (and the virtual underrepresentation of most
outdated studies because of stringent PRISMA criteria) and
the chance of inflated cumulative effect sizes because of
comparisonof ahandful of studies featuringdisproportionate
sample sizes and designs for selected outcomes, no firm
recommendation on the need for lithium dosage adjustment
can be provided at this time, and some women may require
a steady dosage of lithium whenever sudden relapse is a
concern and the harm to the newborn is considered negli-
gible or nil by the prescribing clinician. In addition, abrupt
FIGURE 4. Risk of cardiac anomalies associated with lithium exposure at any time during pregnancy and during the first trimester
compared with unexposed women (either bipolar disorder or general-population controls)
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discontinuation should be avoidedwhenever possible, in line
with the recently released FDA labeling rules for pregnancy
and lactation emphasizing the risks posed by the untreated
disorder if medication is discontinued (33), considering the
lack of sufficient quantitative information allowing any re-
liable meta-analytic pooling on the matter at the time of
writing.
Although on the question of relapse our analysis could
include only two studies, lithium was significantly more ef-
fective for the prevention of mood episode relapse in the
postpartum period than no lithium prophylaxis. This finding
is highly clinically relevant because the risk of bipolar dis-
order relapse during pregnancy has been estimated to be
almost three times higher than in nonpregnant women (7).
Nevertheless, our analyses indicated that lithium has a rel-
atively favorable risk-benefit profile, with an NNT of 3
(“prevention of mood episode relapse during any time of
pregnancy”) counterbalanced by an NNH of 33 (“risk of any
congenital anomaly at any time during pregnancy”).
The results of this systematic review and meta-analysis
must be interpreted within their limitations. First, only a few
studies were available for quantitative meta-analysis. This
lack of data, most pronounced for efficacy outcomes asso-
ciated with lithium maintenance treatment during preg-
nancy, precluded any meta-regression or subgroup analyses
and thereforemay have yielded results that are not definitive.
This limitation pertains mainly to the exploratory meta-
analysis of the outcome “spontaneous abortion,” which in-
cluded only a handful of comparisons, and those outcomes
with high heterogeneity. Therefore, findings in this admit-
tedly challenging-to-study population need to be followed
up by more large controlled and nationwide database stud-
ies, such as those considered in the recent meta-analysis
by Munk-Olsen et al. (8). Furthermore, a publication or
reporting bias may be present concerning some of the out-
comes other than major cardiac malformations (e.g., birth
weight) that were not systematically documented in the
appraised literature. With few notable exceptions (8), the
assessed studies were unclear on whether they excluded per
protocol women who were taking potentially teratogenic
medications other than lithium, were taking other psycho-
tropic medications, or had substance or alcohol misuse and
other maternal conditions potentially influencing fetal or
newborn health outcomes.
Moreover, no quantitative data regarding serum lithium
concentration and temporal lithium exposure were available
aside from the information provided by a single study (34).
Future studies should systematically record lithium dosages
during the peripartum period, also taking into account that
serum levels may fluctuate during pregnancy (35). Further-
more, the data were inadequate for further stratifying the
lithium-unexposed bipolar disorder control subjects by ex-
posure to alternative mood-stabilizing agents, as well as by
additional confounding factors (e.g., typeof bipolar disorder).
Strengths of this study include the large sample size and
the resulting high statistical power, the stratified comparison
between lithium-exposed and unexposed patients with bi-
polar disorder and between lithium-exposed patients and
the general population whenever both control groups were
available, as well as the stratification of the analysis between
any time during pregnancy and exposure during the first
trimester only, whenever possible.
In conclusion, pregnancies in women affected by bipolar
disorder should ideally be planned in order to gradually
reduce the lithium dosage to the lower extreme of the
therapeutic range, in particular during the first trimester,
given that a rapid decrease of lithium dosage increases the
risk of relapse during pregnancy (7). Pregnancy should not
be considered an absolute contraindication to lithium pre-
scription, given the relatively small increase in risk for any
malformation or cardiac malformations, and given that such
events, fortunately, remain rare (prevalences of 4.2% for any
malformation and 1.2% for cardiac malformations), as op-
posed to the frequent relapse of mood episodes during
pregnancy and in the postpartum period (20%270% over
12months) (36, 37), which can themselves have severe health
implications for both mother and fetus or newborn. In par-
ticular, women with affective disorders who are currently
stable on lithiumorwhohavebenefited from lithiumandwho
experienced suboptimal outcomes with treatments other
than lithium should be treatedwith lithium, and at the lowest
effective dosages according to guidelines (11, 34). Finally, as
eloquently noted by Snellen and Malhi (1), while “the aim is
always to achieve the minimum effective dosage, emphasis
needs to be on effective rather thanminimal, and this is often
not the case … and, half treatment represents the worst
possible scenario, as it exposes the fetus to the risks of
treatment and maternal mental illness.”
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